When it comes to MRD, AML ≠ ALL

Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.